🔗 Share this article

As America proceeds with unprecedented changes to its immunization guidelines, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about coronavirus vaccinations during the pandemic and has zeroed in on possible deaths after COVID-19 immunization in her recent time at the Food and Drug Administration.

Planned Shifts to Childhood Vaccine Schedule

Agency leaders planned to reveal major revisions to the childhood immunization program recently, aligning the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US at odds with a large portion of the international standard with insufficient data for benefit. This reveal has been pushed back until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to address the audience at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

The new acting director has often pushed for ending specific pediatric vaccine recommendations in the US so as to align more in line with Denmark, a country with nationalized medicine and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Background

The appointee has little discernible track record in medication creation, regulation or leadership, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a large organization. She is not an expert in pharmaceutical oversight.”

Past directors of CBER would “understand laws and regulations and the science of medication creation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who led CBER have had.”

This division has an enormous workload at the FDA, she stated.

“Many people just focuses on the novel medication approvals, but the generic drug division approves numerous generic drugs. There’s a biosimilars program, OTC medication office and so forth, and each of these need to be supervised,” Dr. Woodcock said. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

There is also, a significant leadership aspect to the role, which manages more than 5,000 employees. “It is a huge management job, if you execute it properly,” the former official said.

Response and Contentious Policies

When asked about inquiries about Dr. Høeg's credentials and whether this appointment indicates greater collaboration among agency officials on immunizations, a representative said that the “questions stem from inaccurate presumptions”.

“This background matches the duties of her job,” the representative said, pointing to the period Høeg spent guiding the agency head on “drug safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a disputed rapid drug-approval program that reportedly troubled her predecessors. “By what process are these medications being picked for this voucher program? Who is making the decisions?” Howard questioned. “There is a lot of confidentiality going on at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards less stringent oversight of most medications, except for shots.”

Documented Past Work on Vaccines

Concerning vaccines, Høeg has a clearer, if concerning, past, Howard observe. She released a analysis using unverified volunteer-provided data to assess the incidence of heart inflammation after COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the current administration encompassed altering guidelines for recently developed shots and discontinuing “non-essential” vaccines, she stated after the election on a podcast. At the agency, Høeg has reportedly suggested excluding adolescent males from getting COVID-19 vaccines.

“She’s an all-around ideologue who begins with her conclusions and works backwards to accommodate the data in a highly disingenuous, fraudulent manner,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of fellow contrarians, {like|